|
|
Post by BD on Aug 7, 2023 15:00:48 GMT -5
|
|
|
|
Post by neil36 on Aug 7, 2023 15:00:50 GMT -5
2Q 2023 Total revenues of $49M; +157% vs. 2Q 2022
2Q 2023 Tyvaso DPI royalties of $19M; +63% vs. 1Q 2023
2Q 2023 Endocrine Business Unit net revenues of $18M; Afrezza net revenues +27% vs. 2Q 2022
2Q 2023 Income from operations of $2M; Non-GAAP income from operations of $8M
|
|
|
|
Post by prcgorman2 on Aug 7, 2023 15:00:57 GMT -5
I stay with -0.03 considering the performance of Tyvaso DPI and the 70% already switched to DPI. Tyvaso DPI royalties at 16M$ and coll and services at 12/12.5M$ Agree I see $45M in Revs. and ($.03) in EPS Was it 70% "switched" or 70% of TRx for the quarter were for Tyvaso DPI? "Switched" sounds like a measurement of an entire patient population, whereas I think the indication was 70% of TRx was for Tyvaso DPI without any statement regarding how many of the existing patients have already made the move. I may have misunderstood, so want to make sure. |
|
|
|
Post by sayhey24 on Aug 7, 2023 15:02:53 GMT -5
“We are excited to report positive income from operations in the second quarter driven by growing patient demand for Tyvaso DPI® and Afrezza as well as manufacturing revenues from Tyvaso DPI,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “In addition, we have optimized our commercial operations supporting Afrezza® and V-Go®, which is expected to get our Endocrine Business Unit to profitability starting in 2024.”
|
|
|
|
Post by tarheelblue004 on Aug 7, 2023 15:04:57 GMT -5
WOOOO HOOOO!! Blowout earnings!! $49M in revenue vs. expectations of only $42M!! POSITIVE NET INCOME vs. expectations of same as last quarter negative $0.04!!
|
|
|
|
Post by prcgorman2 on Aug 7, 2023 15:10:03 GMT -5
Consensus from analysts is that revenue will be $43M with a loss of $.04. They're usually very close. Some here are optimistic we'll hit $45M or even significantly higher. Whatever happens, the optimism here makes today exciting. Hoping tomorrow will be even better  We should know a little after 4:00 p.m. EST. Huh, I thought for sure the (short) sales today meant disappointing news (he said as sarcastically as possible). 
$49M vs $43M consensus estimate. An ~14% miss. Positive earnings? That's profit, right? In 2Q, not 3Q, not 4Q. Thank you Mike & team. Way to hit it out of the park! What a LONG strange trip.
Well, not profit yet, but getting closer! -.02 per share instead of -.04 consensus estimate. The analysts were only off on the loss per share by 100%.
|
|
|
|
Post by neil36 on Aug 7, 2023 15:18:39 GMT -5
My favorite data point so far:
First half of 2022 revenues - $30.8 million
First half of 2023 revenues - $89.2 million
|
|
|
|
Post by sr71 on Aug 7, 2023 15:19:46 GMT -5
I'm seeing $4.84 now in AH (so far).
|
|
|
|
Post by alethea on Aug 7, 2023 15:24:46 GMT -5
My favorite data point so far: First half of 2022 revenues - $30.8 million First half of 2023 revenues - $89.2 million Wait, this has to be wrong. The perpetual fudsters and Negative Nellies keep telling us there is no growth. |
|
|
|
Post by prcgorman2 on Aug 7, 2023 15:31:03 GMT -5
I stay with -0.03 considering the performance of Tyvaso DPI and the 70% already switched to DPI. Tyvaso DPI royalties at 16M$ and coll and services at 12/12.5M$ Agree I see $45M in Revs. and ($.03) in EPS O ye of little faith |
|
|
|
Post by boytroy88 on Aug 7, 2023 15:31:51 GMT -5
$4.87 right now...thought it would go higher given the amount they beat est.
|
|
|
|
Post by brentie on Aug 7, 2023 15:34:16 GMT -5
|
|
|
|
Post by agedhippie on Aug 7, 2023 15:39:16 GMT -5
$4.87 right now...thought it would go higher given the amount they beat est. After hours is always a lottery. See how it goes in the morning, my suspicion is that it's higher. |
|
|
|
Post by kc on Aug 7, 2023 15:44:19 GMT -5
“We are excited to report positive income from operations in the second quarter driven by growing patient demand for Tyvaso DPI® and Afrezza as well as manufacturing revenues from Tyvaso DPI,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “In addition, we have optimized our commercial operations supporting Afrezza® and V-Go®, which is expected to get our Endocrine Business Unit to profitability starting in 2024.” I smell $6.00 per share on Tuesday morning |
|
|
|
Post by castlerockchris on Aug 7, 2023 15:52:34 GMT -5
Wow, Deferred revenue was up 60% or 22.5mm in a quarter where we only lost 5.3mm. The market has got to be looking at that to be as-close-as you need to come to profitability. Ship just 10% of the deferred revenue and we are profitable. Holy cow!
I am not saying we should, could or would ship it. Or that UTHR should take it. Just saying if this continues, it will be hard to not be profitable very, very soon.
|
|
We should know a little after 4:00 p.m. EST.
